

Remarks/Arguments:

Upon entry of the present amendment, newly added claims 15-18 are pending, claims 1-6 and 8-13 having been canceled and claims 7 and 14 having been withdrawn. Rejoinder of the withdrawn method of treatment claims is requested once the product claim is deemed allowable.

Withdrawn claims, claims 7 and 14, have been amended to depend from new claims 15-17. Support for new claims 15 to 17 is provided throughout the application at, for example para. [0190] and Example 94. Support for new claim 18 is provided throughout the application at, for example, para. [0230]. No new matter has been added by this amendment.

35 U.S.C. §112, Second Paragraph (Indefiniteness):

Claims 6 and 10 are rejected as allegedly indefinite. Applicants have canceled these claims rendering the rejection moot. Withdrawal of the rejection is requested.

35 U.S.C. §102(b)

Claims 1-3, 6 and 10 are rejected as allegedly anticipated by Eisai Co., Ltd (WO 03/47577). In order to expedite prosecution and allowance, claims 1-3, 6 and 10 have been cancelled and new claims 15-18 have been added. New claims 15-18 are directed to a particular compound: 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{{5-(methylsulfonyl)pyridin-2-yl}methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide and pharmaceutically acceptable salts thereof. The presently claimed compound is not disclosed in Eisai, nor is there any suggestion of the compound therein.

As amended, the present claims are novel. Withdrawal of the rejection and prompt allowance is respectfully requested.

Conclusion

Applicants would like to thank Examiner Davis for taking time to discuss the claims of the present application with Applicants on March 30, 2010. Applicants believe the claims as amended are in condition for allowance, which action is respectfully requested. Should the Examiner believe otherwise, Applicants request that the Examiner call the undersigned at the number below.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101226-1 US.

Respectfully submitted,

/Christine McCormack/

Name:	Christine McCormack
Dated:	April 26, 2010
Reg. No.:	61331
Phone No.:	781 839-4693

Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451